Hydantin (Phenytoin)

Hydantin (phenytoin) is indicated for several seizure disorders and is employed in clinical practice to reduce the frequency of epileptic events.

• Generalized tonic‑clonic (grand mal) seizures, helping to prevent full‑body convulsions.
• Partial (focal) seizures, with or without secondary generalization, to limit localized abnormal firing.
• Prevention of seizure recurrence after a first unprovoked seizure, reducing the risk of subsequent episodes.
• Adjunctive therapy in status epilepticus when oral administration is feasible and rapid control is needed.
• Long‑term seizure control in patients who have demonstrated a therapeutic response to phenytoin.

• Phenytoin stabilizes neuronal membranes by selectively blocking voltage‑gated sodium channels in the brain. By reducing the influx of sodium ions during the depolarization phase, it prolongs the refractory period of neuronal firing, thereby limiting the rapid repetitive firing that underlies seizure activity. The effect is use‑dependent, meaning it preferentially affects neurons that are firing at high frequencies.

Like many antiepileptic drugs, Hydantin may cause adverse reactions that vary in frequency and severity.

Common

• Dizziness, light‑headedness, or loss of coordination, especially when standing quickly.
• Nausea, vomiting, abdominal pain, or loss of appetite.
• Gingival hyperplasia, which may cause swollen or bleeding gums.
• Skin rash, pruritus, or mild photosensitivity.

Serious

• Severe cutaneous adverse reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hematologic abnormalities including leukopenia, thrombocytopenia, or aplastic anemia.
• Hepatic injury manifested by jaundice, elevated transaminases, or hepatic failure.

Healthcare providers should evaluate several factors before initiating Hydantin to ensure safe and effective use.

• Assess liver and kidney function, as impairment may alter drug clearance.
• Review patient history for cardiac conduction abnormalities, since phenytoin can affect heart rhythm.
• Monitor serum phenytoin levels periodically to maintain therapeutic range and avoid toxicity.
• Counsel patients on the importance of consistent dosing and avoiding abrupt discontinuation.
• Advise regular dental check‑ups because of the risk of gingival overgrowth.
• Consider pregnancy status; phenytoin crosses the placenta and may affect fetal development.
• Evaluate for potential drug allergies, especially to other anticonvulsants.

Hydantin can interact with a variety of medicines, influencing its concentration or the effect of the co‑administered drug.

Avoid

• Concurrent use with other sodium channel blockers such as carbamazepine or lamotrigine, which may increase neurotoxicity.
• Co‑administration with strong enzyme inducers like rifampin or carbamazepine that markedly lower phenytoin levels, reducing efficacy.

Use with caution

• Anticoagulants (e.g., warfarin) – phenytoin may alter INR, requiring closer monitoring.
• Oral contraceptives – phenytoin can reduce hormonal efficacy, increasing risk of breakthrough bleeding.
• CNS depressants (e.g., benzodiazepines, barbiturates) – additive sedative effects may occur.